Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (ADACAL)
cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
Sponsor: Abbott
Terminated
Not enough patient population according to selection criteria to complete the study
Listed as NCT01562951, this PHASE3 trial focuses on Crohn's Disease and Mucosal Inflammation and remains terminated or withdrawn. Sponsored by Abbott, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
- TFS Trial Form Support
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Badalona, Spain , Barcelona, Spain , Bonheiden, Belgium , Brussels, Belgium , Chambray, France , Clichy, France , Córdoba, Spain , Ghent, Belgium , Las Palmas de Gran Canarias, Spain and 17 more locations